ATE467680T1 - Hepatitis-c-virus-impfstoff - Google Patents

Hepatitis-c-virus-impfstoff

Info

Publication number
ATE467680T1
ATE467680T1 AT02773740T AT02773740T ATE467680T1 AT E467680 T1 ATE467680 T1 AT E467680T1 AT 02773740 T AT02773740 T AT 02773740T AT 02773740 T AT02773740 T AT 02773740T AT E467680 T1 ATE467680 T1 AT E467680T1
Authority
AT
Austria
Prior art keywords
nucleic acid
hepatitis
virus vaccine
ns5b
hcv
Prior art date
Application number
AT02773740T
Other languages
English (en)
Inventor
Emilio Emini
David Kaslow
Andrew Bett
John SHIVER
Alfredo Nicosia
Armin Lahm
Alessandra Luzzago
Riccardo Cortese
Stefano Colloca
Original Assignee
Merck Sharp & Dohme
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Angeletti P Ist Richerche Bio filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE467680T1 publication Critical patent/ATE467680T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT02773740T 2001-10-11 2002-10-10 Hepatitis-c-virus-impfstoff ATE467680T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32865501P 2001-10-11 2001-10-11
US36377402P 2002-03-13 2002-03-13
PCT/US2002/032512 WO2003031588A2 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine

Publications (1)

Publication Number Publication Date
ATE467680T1 true ATE467680T1 (de) 2010-05-15

Family

ID=42828995

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02773740T ATE467680T1 (de) 2001-10-11 2002-10-10 Hepatitis-c-virus-impfstoff

Country Status (9)

Country Link
US (3) US7598362B2 (de)
EP (1) EP1436397B1 (de)
JP (1) JP4475561B2 (de)
CN (1) CN1582337B (de)
AT (1) ATE467680T1 (de)
AU (1) AU2002337840B2 (de)
CA (1) CA2461380C (de)
DK (1) DK1436397T3 (de)
WO (1) WO2003031588A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
KR100801123B1 (ko) 2000-08-17 2008-02-05 트리펩 아베 리바비린 함유 백신 및 이것의 사용 방법
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
ES2344253T3 (es) * 2001-10-11 2010-08-23 MERCK SHARP & DOHME CORP. Vacuna contra el virus de la hepatitis c.
CA2461380C (en) * 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
JP2008518591A (ja) * 2004-11-02 2008-06-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 複製欠損アデノウイルスベクターの製造のためのアデノウイルスアンプリコンおよびプロデューサー細胞、その製造方法および用途
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2006088664A2 (en) * 2005-02-17 2006-08-24 The University Of Iowa Research Foundation Flavivirus ns5a proteins for the treatment of hiv
DE102005015005A1 (de) * 2005-04-01 2006-10-05 Qiagen Gmbh Verfahren zur Behandlung einer Biomoleküle enthaltenden Probe
WO2007031867A2 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-stru tural ns3/4a fusion gene
WO2006133911A2 (en) * 2005-06-17 2006-12-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hepatitis c virus nucleic acid vaccine
CN1887350B (zh) * 2005-06-28 2010-10-06 深圳市源兴生物医药科技有限公司 一种重组疫苗及其用途
CN101360821A (zh) * 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
MX2009003873A (es) * 2006-10-12 2009-04-22 Angeletti P Ist Richerche Bio Proteina de fusion de transcriptasa inversa de telomerasa, nucleotidos que la codifican y usos de la misma.
EP2117574A4 (de) 2007-01-24 2010-06-16 Merck Sharp & Dohme Polypeptide zur induzierung einer schützenden immunantwort gegen staphylococcus epidermidis
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009079834A1 (fr) * 2007-12-18 2009-07-02 Peking University People's Hospital Vaccin anti-vhc et procédés de préparation et utilisations de celui-ci
WO2010014567A2 (en) * 2008-08-01 2010-02-04 Merck & Co., Inc. Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
KR101609233B1 (ko) 2008-10-29 2016-04-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개량된 ｈｃｖ 백신 및 이를 이용하는 방법
MX2011005578A (es) 2008-11-26 2011-06-30 Merck Sharp & Dohme Polipeptidos para inducir una respuesta inmune protectora contra staphylococcus aureus.
JP2012509665A (ja) 2008-11-26 2012-04-26 メルク・シャープ・エンド・ドーム・コーポレイション スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
CN102645534B (zh) * 2012-04-26 2015-08-12 杭州市萧山区第一人民医院 基于量子点编码微球芯片检测丙型肝炎病毒的方法
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
US20180000926A1 (en) * 2015-01-15 2018-01-04 Babita Agrawal Methods of inducing an immune response to hepatitis c virus
CN108277230A (zh) * 2018-02-07 2018-07-13 华中科技大学 一种融合dna及其制备的疫苗

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5747339A (en) 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0464287A1 (de) * 1990-06-25 1992-01-08 The Research Foundation for Microbial Diseases of Osaka University Non-A, Non-B Hepatitis Virus genomisches DNS und Antigenpolypeptide
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
CA2117668C (en) * 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
KR100449181B1 (ko) 1995-06-15 2005-01-24 크루셀 홀란드 비.브이. 유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
JP2001520537A (ja) 1997-04-03 2001-10-30 エレクトロフェクト・アクティーゼルスカブ 医薬品と核酸の骨格筋への導入方法
EP0981606A2 (de) 1997-05-12 2000-03-01 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Verfahren und vektor zur hemmung der zell-migration
US6221646B1 (en) * 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
JP2002501737A (ja) 1998-01-30 2002-01-22 ザ・ジェネラル・ホスピタル・コーポレイション Ｃ型肝炎ウイルスの非構造蛋白質による遺伝的免疫感作
AU3489499A (en) 1998-04-14 1999-11-01 Merck & Co., Inc. Needleless administration of polynucleotide formulations
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
US6156588A (en) 1998-06-23 2000-12-05 Vlsi Technology, Inc. Method of forming anti-fuse structure
CA2341516A1 (en) 1998-08-24 2000-03-02 Genzyme Corporation Cationic complexes of polymer-modified adenovirus
WO2000042208A1 (en) 1999-01-14 2000-07-20 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
EP1200622A4 (de) * 1999-07-06 2004-12-22 Merck & Co Inc Hiv impfstoff aus einem das gag-gen tragenden adenovirus
US6627190B2 (en) * 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
JP2003516732A (ja) 1999-11-24 2003-05-20 カイロン コーポレイション 新規なｈｃｖ非構造ポリペプチド
AU5442501A (en) 1999-12-01 2001-07-09 Chiron Corporation Eliciting HCV-specific antibodies
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
AU2001294562B2 (en) 2000-09-15 2007-05-24 Merck & Co., Inc. Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
CA2461380C (en) * 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine

Also Published As

Publication number Publication date
CA2461380A1 (en) 2003-04-17
US8530234B2 (en) 2013-09-10
CA2461380C (en) 2011-03-22
JP4475561B2 (ja) 2010-06-09
JP2005505286A (ja) 2005-02-24
WO2003031588A3 (en) 2003-10-30
EP1436397B1 (de) 2010-05-12
US20090233992A1 (en) 2009-09-17
US7598362B2 (en) 2009-10-06
EP1436397A4 (de) 2005-02-16
CN1582337B (zh) 2011-12-14
US20100129901A1 (en) 2010-05-27
DK1436397T3 (da) 2010-08-09
WO2003031588A2 (en) 2003-04-17
US8142794B2 (en) 2012-03-27
CN1582337A (zh) 2005-02-16
AU2002337840B2 (en) 2007-08-09
US20040247615A1 (en) 2004-12-09
EP1436397A2 (de) 2004-07-14

Similar Documents

Publication Publication Date Title
ATE467680T1 (de) Hepatitis-c-virus-impfstoff
Zhong et al. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase
Kunkel et al. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein
Hong et al. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase
Tanaka et al. Structure of the 3'terminus of the hepatitis C virus genome
Steffens et al. The RNA-dependent RNA polymerases of different members of the family Flaviviridae exhibit similar properties in vitro
Sun et al. De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase
ATE258227T1 (de) Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv)
Wood et al. Hepatitis C virus 3′ X region interacts with human ribosomal proteins
EP1256628A3 (de) Hepatitis C Virus (HCV) NS5B RNA Polymerase und davon abgeleitete Mutanten
Roussel et al. Characterization of the expression of the hepatitis C virus F protein
DK0783321T3 (da) VR-2332 viral nucleotidsekvens og fremgangsmåder til anvendelse
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
HUP0203305A2 (hu) Fertőző klónok
DK1026262T3 (da) Oligonukleotidprimere til effektiv detektering af hepatitis C-virus (HCV) og fremgangsmåder til anvendelse deraf
Neddermann et al. The nonstructural proteins of the hepatitis C virus: structure and functions.
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
ATE142700T1 (de) Genetische manipulationen mit von rna-viren abgeleiteten sequenzen enthaltendem rekombinantem dna
DK1412505T3 (da) DNA-sekvenser til regulering af transkription
DK0698216T4 (da) Fremgangsmåder til typebestemmelse af hepatitis-C-virus og anvendte reagenser heri
Butkiewicz et al. Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
Waris et al. Two-step affinity purification of the hepatitis C virus ribonucleoprotein complex
WO2003031934A3 (en) Identification of oligonucleotides for the capture, detection and quantitation of hepatitis b viral dna

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1436397

Country of ref document: EP